Almirall

Rising Global Wealth And Aging Populations Will Expand Dermatology Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 10 Analysts

Published

09 Sep 25

AnalystHighTarget's Fair Value

€16.57

32.0% undervalued

09 Sep

€11.26

31.6%

You can edit this narrative until Sep 9 9:27 PM. Then, changes will post as Updates.

Author's Valuation

€16.6

32.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

€16.57

32.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

9.40%

Pharma revenue growth rate

0.60%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.49%

Calculation

€205.37m

Earnings '28

21.84x

PE Ratio '28

€4.48b

Market Cap '28

€4.48b

Market Cap '28

214.79m

No. shares '28

€20.88

Share Price '28

€20.88 Share Price '28

Discounted to 2025 @ 7.49% p.a.

€16.81

Fair Value '25